Last updated: June 5, 2026

Back to directory

DoMore Diagnostics Histotype Px Colorectal medical AI product profile

Digital pathology biomarker that analyzes colorectal cancer histology slides to support recurrence and survival risk stratification for adjuvant-treatment review.

Screenshot of the official DoMore Diagnostics Histotype Px Colorectal product page
Digital pathology

Best fit

Oncology and pathology teams exploring AI-supported colorectal cancer risk stratification where results are reviewed alongside TNM staging, ctDNA, guidelines, and clinician judgment.

Primary use case
AI-powered digital biomarker for stage II and stage III colorectal cancer outcome prediction from routine H&E histology slides
Audience
Colorectal cancer pathology teams, oncology programs, translational research groups, and digital pathology platform users
Risk level
High
Pricing signal
Enterprise diagnostic, oncology, and platform-partner pricing; request current regional and integration terms.
Official sources
4 official sources

Compare within workflow: Digital pathology · comparison shortlist · source index

Regulatory, privacy, evidence, and workflow lens

Product-specific review. These product-specific signals summarize what the cited sources imply before treating DoMore Diagnostics Histotype Px Colorectal as safe for a local clinical, operational, or research workflow.

Regulatory / FDAConfirm CE-IVD or other local status for the exact version, market, stage II/III colorectal indication, and whether the deployment is diagnostic, research, or platform-enabled.
PrivacyReview slide upload, hosting, customer-contract data roles, platform-partner processing, retention, access controls, audit trails, and whether oncology data leaves the lab or hospital environment.
EvidenceCheck validation studies, endpoint definitions, patient population, scanner/site diversity, calibration, and whether evidence supports the actual treatment decision under consideration.
WorkflowBest used as a tumor-board or oncology decision-support input where pathologists and oncologists review the biomarker beside conventional pathology, ctDNA, and guideline-based factors.

Where DoMore Diagnostics Histotype Px Colorectal fits

DoMore Diagnostics describes Histotype Px Colorectal as a CE-IVD-marked deep-learning digital biomarker for stage II and III colorectal cancer prognosis using routine H&E slides, with published and ongoing validation work and integrations or partnerships with digital pathology platforms including PathAI, Sectra, Proscia, and Paige.

Not for: Treatment selection, chemotherapy de-escalation, or patient counseling without oncologist review, local validation, and regulatory or guideline fit for the jurisdiction.

What to verify before using DoMore Diagnostics Histotype Px Colorectal

Source links

Use these links to confirm current claims, terms, regulatory status, pricing, and deployment requirements.

Related medical AI products